Myanmar vs New Zealand: Access to anti-retroviral drugs, female
Myanmar
78.0%
in 2024
New Zealand
80.0%
in 2024
Myanmar rank
60th
New Zealand rank
57th
Access to anti-retroviral drugs, female over time
- Myanmar
- New Zealand
How they compare
New Zealand currently reports 80.0% against 78.0% in Myanmar, a difference of 2.0%.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was New Zealand ahead.
Myanmar ranks 60th and New Zealand ranks 57th of 141 countries.
Across the 3 decades both report, Myanmar averaged higher in 1 and New Zealand in 2.
Head to head by decade
| Decade | Myanmar | New Zealand | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 2.5% | 47.5% | 45.0% | New Zealand |
| 2010s | 39.2% | 64.6% | 25.4% | New Zealand |
| 2020s | 75.6% | 73.8% | 1.8% | Myanmar |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Myanmar or New Zealand?
- New Zealand, at 80.0% against 78.0% in Myanmar as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Myanmar and New Zealand?
- 2.0%, with New Zealand ahead.
- How many years of comparable data are there for Myanmar and New Zealand?
- 25 years are reported by both, from 2000 to 2024.
- How do Myanmar and New Zealand rank globally for access to anti-retroviral drugs, female?
- Myanmar ranks 60th and New Zealand ranks 57th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.